BiotechTube
TriAltus Bioscience

TriAltus Bioscience

Boulder, United States· Est.
trialtusbioscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

TriAltus Bioscience, founded in 2021, is a private biotech supplier specializing in high-quality, cost-effective recombinant enzymes. The company's competitive edge is its proprietary CLīM™ purification platform, which enables single-step purification of ultra-pure proteins directly from complex lysates, reducing manufacturing costs. This technology is validated by its use in the lab of Nobel laureate Dr. Jennifer Doudna for CRISPR enzyme production. TriAltus operates a 'Pilot2Partnership' program, offering a services-based model to develop custom proteins before transitioning to a product supply partnership.

BiologicsAntibodies

Technology Platform

CLīM™ purification platform: A proprietary, single-step affinity purification technology based on the ultra-high affinity (femtomolar) CL7/Im7 system derived from colicin E7 DNase. It enables purification of recombinant proteins directly from high-salt lysates, yielding high purity with a simplified workflow and lower manufacturing cost.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The rapidly expanding CRISPR and genomic research tools market presents a major growth opportunity.
The CLīM™ platform's applicability to any recombinant protein also opens doors in diagnostics, synthetic biology, and industrial enzymes beyond the core genomics focus.

Risk Factors

Intense competition from large, established life science reagent companies and other startups poses a significant market risk.
The business is also highly dependent on maintaining the technological edge of its single proprietary platform, and faces execution risks in scaling manufacturing and commercial operations.

Competitive Landscape

TriAltus competes with large, diversified life science tools companies like New England Biolabs, Thermo Fisher Scientific, and Merck, which offer broad enzyme portfolios. It also competes with specialized CRISPR reagent suppliers and CROs offering protein expression services. Its key differentiators are the claimed price-to-performance ratio enabled by the CLīM™ platform and its 'Pilot2Partnership' custom service approach.

More companies in CRISPR / Gene Editing →More companies in United States →